Loading clinical trials...

TERMINATED

Brain Study of Patients With Frontal Lobe Dementia and Parkinsonian Disorders

Regional Cerebral Utilization of Glucose in Patients With a Diagnosis of Frontal Lobe Dementia, Atypical Parkinsonian Disorder, and Other Basal Ganglia Disorders

NCT00001178•National Institute of Neurological Disorders and Stroke (NINDS)

View on ClinicalTrials.gov

Summary

The Cognitive Neuroscience Section of the National Institute of Neurological Disorders and Stroke proposes to continue its cross-sectional and longitudinal studies of cerebral metabolism in frontal lobe dementias and atypical basal ganglia disorders. These studies include repeated assessments of neuropsychological and brain anatomical and metabolic function in subjects with these important and possibly related brain disorders.

Detailed Description

Objective To continue the cross-sectional and longitudinal studies performed by the Cognitive Neuroscience Section of NINDS on the neuroanatomy, cerebral metabolism, neuropsychology, and genetics of frontotemporal dementia, corticobasal syndrome, and related brain disorders. Study population Frontal lobe dementias and atypical basal ganglia disorders including frontotemporal dementia, corticobasal syndrome, and related brain disorders. Design A cross-sectional assessment of neuropsychological, brain anatomical and metabolic function, and genetic measures in subjects with these disorders. Outcome measures MRI, FDG-PET, neuropsychological and clinical tests, genetics, and neuropathology.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Subjects will be recruited from the NIH referral center, neurological and psychiatric clinics, from self or family referral in response to advertisements or from private physicians. Healthy volunteers will include subjects who are considered at-risk for the development of FTD or CBS and subjects who serve as normal controls matched for key characteristics with the patients.
•Diagnosis of possible / probable FTD or CBS
•Caregiver willing and able to accept the responsibilities involved in the study

Exclusion Criteria

•Pregnant women. Women of childbearing potential will be screened by history for the possibility of pregnancy and undergo a urine pregnancy test. These women will be excluded from the imaging portions of the protocol.
•Behavioral symptoms that would preclude the gathering of data for the study
•Other medical or social condition that would preclude participation in the opinion of the investigators

Locations (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, United States

Key Dates

Start Date

January 19, 1981

Completion Date

December 17, 2012

Last Updated

December 12, 2019

Enrollment

597

ACTUAL participants

Conditions

Alzheimer's DiseaseDementiaDown's Syndrome

ACP-204 in Adults With Alzheimer's Disease Psychosis

NCT06159673

Alzheimer's Disease Psychosis

View study

RECRUITING

Lombard Cohort of Brain Health Services

NCT07457138

Subjective Cognitive Decline (SCD)Functional Cognitive Disorder+2 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 12, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Brain Study of Patients With Frontal Lobe Dementia and Parkinsonian Disorders

Inclusion Criteria

Exclusion Criteria

ACP-204 in Adults With Alzheimer's Disease Psychosis

Lombard Cohort of Brain Health Services

[18F]F-DOPA Imaging in Patients With Autonomic Failure

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Testing the Pain Clinical Practice Guideline